NImmune Biopharma Presented New Data at ACG 2026 Supporting the Efficacy and Safety of Innovative LANCL2 Medicines Targeting a Novel Mechanism in Hard-to-Treat IBD
BLACKSBURG, Va.--(BUSINESS WIRE)-- #ACG2026--NImmune reports ACG 2026 data supporting omilancor and NIM-1324 in hard-to-treat IBD, highlighting LANCL2 and its TITAN-X AI platform.